Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ltz Therapeutics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, GUSTILO, ESTELLA M, who is identified as the busiest examiner for the company. The involvement of 1 distinct art unit indicates a very specific technical focus for the current prosecution.
GUSTILO, ESTELLA M is responsible for 1 busiest examiner pending action, which matches the total count of 1 pending office action for the portfolio. This concentration suggests that the company's intellectual property efforts are currently focused on a single technical challenge within Biotechnology & Pharmaceuticals. The 1 distinct art unit involved confirms that the work is not distributed across different USPTO departments.
For a practitioner, the primary task is to address the specific concerns of GUSTILO, ESTELLA M regarding the 1 busiest examiner pending action. Because there is only 1 distinct examiner and 1 distinct art unit, the prosecution process is highly streamlined. The outcome of this 1 pending office action will determine the immediate success of the company's current patenting strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18625012 | MULTISPECIFIC ANTIBODIES TARGETING CD79B/CD3 AND THE USES THEREOF | GUSTILO, ESTELLA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18625012 | MULTISPECIFIC ANTIBODIES TARGETING CD79B/CD3 AND THE USES THEREOF | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18625012 | MULTISPECIFIC ANTIBODIES TARGETING CD79B/CD3 AND THE USES THEREOF | GUSTILO, ESTELLA M | 1646 | §103§112 | Non-Final OA | — | Pending | Apr 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLtz Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Estella M Gustilo has the most, with 1 of Ltz Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
